Publications by authors named "Sophia A Shahin"
Article Synopsis
- * They created a model where human ovarian cancer cells formed tumors on the egg membrane, closely mimicking actual tumors found in patients.
- * The study found that PMO nanoparticles loaded with doxorubicin effectively eliminated tumors with minimal damage to the embryo, unlike free doxorubicin, highlighting the potential of this delivery system for future treatments.
TWIST protein is critical to development and is activated in many cancers. TWIST regulates epithelial-mesenchymal transition, and is linked to angiogenesis, metastasis, cancer stem cell phenotype, and drug resistance. The majority of epithelial ovarian cancer (EOC) patients with metastatic disease respond well to first-line chemotherapy but most relapse with disease that is both metastatic and drug resistant, leading to a five-year survival rate under 20%.
View Article and Find Full Text PDFBackground: Most cancer deaths result from tumor cells that have metastasized beyond their tissue of origin, or have developed drug resistance. Across many cancer types, patients with advanced stage disease would benefit from a novel therapy preventing or reversing these changes. To this end, we have investigated the unique WR domain of the transcription factor TWIST1, which has been shown to play a role in driving metastasis and drug resistance.
View Article and Find Full Text PDFArticle Synopsis
- Epithelial ovarian cancer (EOC) is a highly lethal cancer due to late diagnosis and recurring drug resistance, prompting the need for innovative treatments.
- TWIST, a transcription factor associated with cancer progression and resistance, is identified as a promising target for therapy.
- The study shows that TWIST siRNA delivered by nanoparticles can effectively reduce drug resistance and tumor burden in EOC, suggesting a potential strategy for managing metastatic and resistant cancers.